Literature DB >> 8455072

FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.

J M Hoffman1, H A Waskin, T Schifter, M W Hanson, L Gray, S Rosenfeld, R E Coleman.   

Abstract

Structural imaging studies such as CT or MRI are not able to accurately differentiate infectious from malignant cerebral lesions in patients with AIDS. We studied 11 individuals with AIDS and central nervous system (CNS) lesions with 18F-fluoro-2-deoxyglucose (FDG) and positron emission tomography (PET). FDG-PET was able to accurately differentiate between a malignant (lymphoma) and nonmalignant etiology for the CNS lesions. Both qualitative visual inspection of the images as well as semiquantitative analysis using count ratios was performed and revealed similar results. FDG-PET may be useful in the management of AIDS patients with CNS lesions since high FDG uptake most likely represents a malignant process which should be biopsied for confirmation rather than treated presumptively as infectious.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8455072

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  36 in total

1.  Brain Abscess, Subdural Empyema, and Intracranial Epidural Abscess.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques.

Authors:  A M Scharko; S B Perlman; J M Hanson; H Uno; C D Pauza
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients.

Authors:  Robert J Young; Munir V Ghesani; Nolan J Kagetsu; Andrew J Derogatis
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

4.  A plea for the elective inclusion of the brain in routine whole-body FDG PET.

Authors:  Tarik Belhocine; Stefan Markus Weiner; Ingo Brink; Peter Paul De Deyn; Jan Roland; Thierry Van der Borght; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

5.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

6.  Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Nobuyuki Kawai; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

Review 7.  Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond.

Authors:  Mike Sathekge; Alicia McFarren; Ekaterina Dadachova
Journal:  Nucl Med Commun       Date:  2014-08       Impact factor: 1.690

8.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; H Goldschmidt; W J Lorenz; W Maier-Borst; G van Kaick
Journal:  Eur J Nucl Med       Date:  1995-05

Review 9.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 10.  Positron emission tomography in patients suffering from HIV-1 infection.

Authors:  Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.